Omnix Medical
Jerusalem, Israel· Est.
Omnix Medical engineers stable, selective antimicrobial peptides to address the global crisis of antibiotic‑resistant infections.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Omnix Medical engineers stable, selective antimicrobial peptides to address the global crisis of antibiotic‑resistant infections.
Infectious Diseases
Technology Platform
Engineered antimicrobial peptides with enhanced stability and bacterial selectivity achieved through synthetic and biochemical modifications.
Opportunities
The urgent global need for novel antibiotics against MDR Gram‑negative pathogens creates a clear market for OMN51, and successful IND filing could unlock partnerships with large pharma.
Risk Factors
Clinical safety uncertainties, scale‑up manufacturing challenges for peptide drugs, and intense competition from both small‑molecule and other peptide‑based anti‑infectives.
Competitive Landscape
Omnix competes with traditional antibiotics and emerging peptide platforms; its differentiation is the engineered stability and selectivity of its AMPs, which may offer a unique safety and efficacy profile.